Despite new 95% curative treatments being listed on the Pharmaceutical Benefits Scheme (PBS) at a huge cost to the taxpayer, the provision of treatment is failing to connect with hundreds of thousands of Australians living with hepatitis C.
This means the Government is at risk of missing its target to eradicate hepatitis C by 2030 and risks spending far more money on the treatments than could otherwise be necessary.
Recent data shows fewer than half as many people are now accessing the direct acting antivirals as were being treated immediately after they were first listed on the PBS in March 2016.
Hepatitis ACT does not agree with mainstream media characterization that life-saving medicines are being ignored by people living with hepatitis C. The reasons for declining treatment rates are complex and various. Blaming affected populations for ‘failing’ anything completely misses the point.